Last reviewed · How we verify

Fycompa — Competitive Intelligence Brief

Fycompa (PERAMPANEL) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Noncompetitive AMPA Glutamate Receptor Antagonist [EPC]. Area: Neuroscience.

marketed Noncompetitive AMPA Glutamate Receptor Antagonist [EPC] Glutamate receptor ionotropic AMPA Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Fycompa (PERAMPANEL) — Catalyst Pharms. Fycompa works by blocking the AMPA glutamate receptor, which is involved in the transmission of nerve impulses.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Fycompa TARGET PERAMPANEL Catalyst Pharms marketed Noncompetitive AMPA Glutamate Receptor Antagonist [EPC] Glutamate receptor ionotropic AMPA 2012-01-01
Fycompa Fycompa Eisai Inc. marketed Glutamate receptor ionotropic AMPA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Noncompetitive AMPA Glutamate Receptor Antagonist [EPC] class)

  1. Catalyst Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fycompa — Competitive Intelligence Brief. https://druglandscape.com/ci/perampanel. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: